Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
39 Leser
Artikel bewerten:
(0)

The Human Microbiome: Advancing New Frontiers in a Rapidly Emerging Market - Commercial Aspects of Microbiome Research and Development - Research and Markets

DUBLIN, May 18, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "The Human Microbiome: Advancing New Frontiers in a Rapidly Emerging Market" report to their offering.

The field of Human Microbiome research and development is apparently one of the most popular hubs of the biotechnology industry. While the Human Microbiome Project, MetaHIT and other huge studies of human microbiota, have garnered a lot of attention over that past few years, the microbiome space has literally exploded in terms of both basic and applied biomedical research.

This report focuses on biomedical aspects of research, development, and commercial endeavors in the human microbiome space. It includes essential background information, evolution of the field, advances in basic research, events in the emerging commercial market, deal activity, interviews with experts, and trends in microbiome research and commerce. Primary sources of information for this report include the scientific literature, discussions with experts, and an online survey of individuals working in this space.

This Report Covers:

- Advances in Research on the Human Microbiome

- Commercial Aspects of Microbiome Research and Development

- Current Deal Activity

- Over 25 Companies Profiled

- Survey data from exclusive Insight Pharma Reports Survey

Interviews with:

- Lee Jones, Founder CEO, Rebiotix

- Brian Varnum, PhD, Chief Development Officer C3 Jian

- Yanjiao Zhou, MD, PhD, Research Scientist, The Jackson Laboratory for Genomic Medicine

- Dr Bernard Malfroy-Camine, President and CEO, ViThera Pharmaceuticals

- Mark L. Heiman, Ph.D., FTOS, Vice President, Research and CSO, MicroBiome Therapeutics (formerly NuMe Health)

- Larry Weiss, MD, Chief Medical Officer, AOBiome, LLC

- Karen E. Nelson, PhD, President, J. Craig Venter Institute (JCVI), Head, Microbiome Program, Human Longevity Institute (HLI)

- Sara Malcus, PhD, CEO, MetaboGen AB

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - History and Evolution

Chapter 3 - Advances in Research on the Human Microbiome

Chapter 4 - Commercial Aspects of Microbiome Research and Development

Chapter 5 - Market Dynamics

Chapter 6 - Observations and Conclusions

Chapter 7 - Interview Transcripts

Companies Mentioned

- AdvancingBio Inc.

- AOBiome LLC

- Assembly Biosciences, Inc.:

- AvidBiotics Corp.:

- C3 Jian, Inc.

- Diversigen, Inc.

- Eligo Bioscience

- Enterome Bioscience SA

- Evelo Therapeutics

- Evolve BioSystems Inc.

- ExeGi Pharma LLC

- Human Longevity, Inc.

- Interface Diagnostics

- Intrexon Corporation

- MaaT Pharma

- MetaboGen AB

- Microbiome Therapeutics LLC

- OpenBiome, Inc.

- Pureflora, Inc.

- Rebiotix Inc.

- Seres Therapeutics

- Symbiotic Health Inc.

- Symbiotix Biotherapies, Inc.

- Synlogic Therapeutics

- Synthetic Biologics Inc

- ViThera Pharmaceuticals Inc.

- Xycrobe Therapeutics, Inc.

For more information visit http://www.researchandmarkets.com/research/v4p9fs/the_human

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.